Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma

Martine L. M. Lamfers, Davide Gianni, Ching-Hsuan Tung, Sander Idema, Frederik H. E. Schagen, Jan E. Carette, Paul H. A. Quax, Victor W. van Beusechem, W. Peter Vandertop, Clemens M. F. Dirven, E. Antonio Chiocca, Winald R. Gerritsen

Research output: Contribution to journalArticleAcademicpeer-review

48 Citations (Scopus)

Abstract

Oncolytic adenoviruses exhibiting tumor-selective replication are promising anticancer agents. Insertion and expression of a transgene encoding tissue inhibitor of metalloproteinase-3 (TIMP-3), which has been reported to inhibit angiogenesis and tumor cell infiltration and induce apoptosis, may improve the antitumor activity of these agents. To assess the effects of TIMP-3 gene transfer to glioma cells, a replication-defective adenovirus encoding TIMP-3 (Ad.TIMP-3) was employed. Ad.TIMP-3 infection of a panel of glioma cell cultures decreased the proliferative capacity of these cells and induced morphologic changes characteristic for apoptosis. Next, a conditionally replicating adenovirus encoding TIMP-3 was constructed by inserting the TIMP-3 expression cassette into the E3 region of the adenoviral backbone containing a 24-bp deletion in E1A. This novel oncolytic adenovirus, AdDelta24TIMP-3, showed enhanced oncolytic activity on a panel of primary cell cultures and two glioma cell lines compared with the control oncolytic virus AdDelta24Luc. In vivo inhibition of matrix metalloproteinase (MMP) activity by AdDelta24TIMP-3 was shown in s.c. glioma xenografts. The functional activity of TIMP-3 was imaged noninvasively using a near-IR fluorescent MMP-2-activated probe. Tumoral MMP-2 activity was significantly reduced by 58% in the AdDelta24TIMP-3-treated tumors 24 hours after infection. A study into the therapeutic effects of combined oncolytic and antiproteolytic therapy was done in both a s.c. and an intracranial model for malignant glioma. Treatment of s.c. (U-87MG) or intracranial (U-87deltaEGFR) tumors with AdDelta24TIMP-3 and AdDelta24Luc both significantly inhibited tumor growth and prolonged survival compared with PBS-treated controls. However, expression of TIMP-3 in the context of AdDelta24 did not significantly affect the antitumor efficacy of this oncolytic agent
Original languageEnglish
Pages (from-to)9398-9405
Number of pages8
JournalCancer research
Volume65
Issue number20
DOIs
Publication statusPublished - 15 Oct 2005

Keywords

  • Adenoviridae/genetics
  • Animals
  • Cell Growth Processes/genetics
  • Cell Line, Tumor
  • Gene Transfer Techniques
  • Glioma/enzymology
  • Humans
  • Matrix Metalloproteinase 2/metabolism
  • Matrix Metalloproteinase Inhibitors
  • Mice
  • Mice, Nude
  • Tissue Inhibitor of Metalloproteinase-3/biosynthesis
  • Virus Replication
  • Xenograft Model Antitumor Assays

Cite this